ENLIVEN THERAPEUTICS, INC. Unrealized Gain (Loss) on Investments
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Unrealized Gain (Loss) on Investments of $12.00 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-10-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2023-02-10
- ENLIVEN THERAPEUTICS, INC. unrealized gain (loss) on investments for the quarter ending 2022-09-30 was $31.00K.
- ENLIVEN THERAPEUTICS, INC. unrealized gain (loss) on investments for the quarter ending 2022-06-30 was $16.00K.
- ENLIVEN THERAPEUTICS, INC. unrealized gain (loss) on investments for the quarter ending 2022-03-31 was -$35.00K.
- ENLIVEN THERAPEUTICS, INC. unrealized gain (loss) on investments for the quarter ending 2021-12-31 was -$14.00K.
- ENLIVEN THERAPEUTICS, INC. unrealized gain (loss) on investments for fiscal 2021 was -$20.00K.
- ENLIVEN THERAPEUTICS, INC. unrealized gain (loss) on investments for fiscal 2020 was -$28.00K.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 3 month as first filed | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 12 month |
|---|---|---|---|---|---|
| 2022-09-30 | $31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | $47.00K derived: sum of 2 quarters · filed 2022-10-25 | $12.00K 10-Q · filed 2022-10-25 | -$2.00K derived: sum of 4 quarters · filed 2023-02-10 | |
| 2022-06-30 | $16.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$19.00K 10-Q · filed 2022-08-03 | -$33.00K derived: sum of 3 quarters · filed 2023-02-10 | -$35.00K derived: sum of 4 quarters · filed 2023-02-10 | |
| 2022-03-31 | -$35.00K 10-Q · filed 2022-05-06 | -$49.00K derived: sum of 2 quarters · filed 2023-02-10 | -$51.00K derived: sum of 3 quarters · filed 2023-02-10 | -$53.00K derived: sum of 4 quarters · filed 2023-02-10 | |
| 2021-12-31 | -$14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | -$16.00K derived: sum of 2 quarters · filed 2023-02-10 | -$18.00K derived: sum of 3 quarters · filed 2023-02-10 | -$20.00K 10-K · filed 2023-02-10 | |
| 2021-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | -$4.00K derived: sum of 2 quarters · filed 2022-10-25 | -$6.00K 10-Q · filed 2022-10-25 | -$26.00K derived: sum of 4 quarters · filed 2022-10-25 | |
| 2021-06-30 | -$2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$4.00K 10-Q · filed 2022-08-03 | -$24.00K derived: sum of 3 quarters · filed 2022-08-03 | -$48.00K derived: sum of 4 quarters · filed 2022-08-03 | |
| 2021-03-31 | -$2.00K 10-Q · filed 2022-05-06 | -$3.00K 10-Q · filed 2021-05-11 | -$22.00K derived: sum of 2 quarters · filed 2022-05-06 | -$46.00K derived: sum of 3 quarters · filed 2022-05-06 | $18.00K derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | -$20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$44.00K derived: sum of 2 quarters · filed 2022-03-15 | $20.00K derived: sum of 3 quarters · filed 2022-03-15 | -$28.00K 10-K · filed 2022-03-15 | |
| 2020-09-30 | -$24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $40.00K derived: sum of 2 quarters · filed 2021-11-09 | -$8.00K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $64.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $16.00K 10-Q · filed 2021-08-06 | |||
| 2020-03-31 | -$48.00K 10-Q · filed 2021-05-11 | ||||
| 2019-09-30 | $30.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |